IC
ALLO icon

IEQ Capital’s Allogene Therapeutics ALLO Stock Holding History

IEQ Capital’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.21M Sell
580,371
-33,818
-6% -$74.3K 0.01% 1031
2026
Q1 		$1.5M Buy
614,189
+178,922
+41% +$359K 0.01% 882
2025
Q4 		$596K Buy
435,267
+59,209
+16% +$78.1K ﹤0.01% 1250
2025
Q3 		$466K Buy
376,058
+189,880
+102% +$226K ﹤0.01% 1330
2025
Q2 		$210K Buy
186,178
+120,000
+181% +$159K ﹤0.01% 1592
2025
Q1 		$96.6K Hold
66,178
– – ﹤0.01% 1484
2024
Q4 		$141K Hold
66,178
– – ﹤0.01% 1245
2024
Q3 		$185K Hold
66,178
– – ﹤0.01% 1069
2024
Q2 		$154K Sell
66,178
-175
-0.3% -$516 ﹤0.01% 932
2024
Q1 		$297K Hold
66,353
– – ﹤0.01% 774
2023
Q4 		$213K Buy
66,353
+175
+0.3% +$496 ﹤0.01% 825
2023
Q3 		$210K Buy
66,178
+20,648
+45% +$90.5K ﹤0.01% 825
2023
Q2 		$226K Buy
45,530
+2,530
+6% +$13.7K ﹤0.01% 774
2023
Q1 		$212K Buy
43,000
+21,000
+95% +$135K ﹤0.01% 805
2022
Q4 		$138K Sell
22,000
-21,000
-49% -$194K ﹤0.01% 755
2022
Q3 		$464K Hold
43,000
– – 0.01% 549
2022
Q2 		$490K Hold
43,000
– – 0.01% 478
2022
Q1 		$392K Hold
43,000
– – 0.01% 565
2021
Q4 		$642K Sell
43,000
-47
-0.1% -$829 0.01% 400
2021
Q3 		$1.11M Buy
43,047
+47
+0.1% +$1.12K 0.03% 279
2021
Q2 		$1.12M Hold
43,000
– – 0.03% 239
2021
Q1 		$1.52M Hold
43,000
– – 0.06% 165
2020
Q4 		$1.08M Hold
43,000
– – 0.05% 160
2020
Q3 		$1.62M Hold
43,000
– – 0.09% 125
2020
Q2 		$1.84M Hold
43,000
– – 0.12% 110
2020
Q1 		$836K Hold
43,000
– – 0.07% 161
2019
Q4 		$1.12M Buy
+43,000
New +$1.18M 0.1% 140

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

IEQ Capital's ALLO Position: Q2 2026 in Review

IEQ Capital reduced its Allogene Therapeutics (ALLO) stake by 5.5% in Q2 2026, selling an estimated $74.3K and leaving 580,371 shares worth $1.21M. The position accounts for 0.01% of the portfolio, ranked #1031.

IEQ Capital first reported a position in ALLO in Q4 2019 and has held it in 27 quarters since. The position peaked at $1.84M in Q2 2020. 210 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • IEQ Capital held 580,371 shares of Allogene Therapeutics worth $1.21M as of Q2 2026.
  • IEQ Capital sold 33,818 Allogene Therapeutics shares in Q2 2026, an estimated $74.3K.
  • Allogene Therapeutics made up 0.01% of IEQ Capital's portfolio in Q2 2026, its #1031 holding.
  • IEQ Capital first reported a position in Allogene Therapeutics in Q4 2019 and has held it in 27 quarters since.
  • IEQ Capital's Allogene Therapeutics position peaked at $1.84M in Q2 2020.
  • 210 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on IEQ Capital's 13F filing for Q2 2026, filed 11 Aug 2026.